<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Disorders that cause hypothyroidism</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Disorders that cause hypothyroidism</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Disorders that cause hypothyroidism</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 12, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hypothyroidism can result from a defect anywhere in the hypothalamic-pituitary-thyroid axis. In the vast majority of cases, it is caused by thyroid disease (primary hypothyroidism). Much less often it is caused by decreased secretion of thyroid-stimulating hormone (TSH) from the anterior pituitary gland or by decreased secretion of thyrotropin-releasing hormone (TRH) from the hypothalamus  (<a class="graphic graphic_table graphicRef67769" href="/z/d/graphic/67769.html" rel="external">table 1</a>).</p><p>The cause of hypothyroidism should be identified in every patient for the following reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypothyroidism may be transient and require no or only short-term therapy, as in patients with painless thyroiditis or postpartum thyroiditis. (See  <a class="medical medical_review" href="/z/d/html/7824.html" rel="external">"Overview of thyroiditis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It may be caused by a drug, such as <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> or an iodine-containing drug, and disappear when the drug is discontinued.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It may be the first or only manifestation of hypothalamic or pituitary disease.</p><p></p><p>The cause can often be identified, or at least strongly inferred, from the history and physical examination.</p><p>This topic will review the major causes of hypothyroidism. The diagnostic approach to and treatment of hypothyroidism are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults"</a> and  <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PRIMARY HYPOTHYROIDISM</span><span class="headingEndMark"> — </span>In patients with hypothyroidism caused by disease of the thyroid gland, decreased secretion of thyroxine (T4) and triiodothyronine (T3) leads to a reduction in the serum concentrations of the two hormones, which results in a compensatory increase in TSH secretion. Thus, the combination of a low serum T4 and a high serum TSH concentration both confirms the diagnosis of hypothyroidism and indicates that it is due to primary thyroid disease.</p><p>We recognize two degrees of primary hypothyroidism:</p><p class="bulletIndent1"><span class="glyph">●</span>Subclinical hypothyroidism – Subclinical hypothyroidism is defined as a high serum TSH concentration in the presence of normal serum free T4 and T3 concentrations. This combination of findings reflects the great sensitivity of TSH secretion to very small reductions in thyroid secretion. These patients have few, if any, symptoms and signs of hypothyroidism. (See  <a class="medical medical_review" href="/z/d/html/7883.html" rel="external">"Subclinical hypothyroidism in nonpregnant adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Overt hypothyroidism – Overt hypothyroidism is defined as a high serum TSH concentration in the presence of a low serum free T4 concentration. Most of these patients have symptoms and signs of hypothyroidism. (See  <a class="medical medical_review" href="/z/d/html/7846.html" rel="external">"Clinical manifestations of hypothyroidism"</a>.)</p><p></p><p>All of the thyroid disorders considered below can cause either subclinical or overt hypothyroidism.</p><p class="headingAnchor" id="H3"><span class="h2">Chronic autoimmune (Hashimoto's) thyroiditis</span><span class="headingEndMark"> — </span>The most common cause of hypothyroidism in iodine-sufficient areas of the world is chronic autoimmune (Hashimoto's) thyroiditis, which is caused by cell- and antibody-mediated destruction of thyroid tissue [<a href="#rid1">1</a>]. The disorder has two forms: goitrous and atrophic. They differ in the extent of lymphocytic infiltration, fibrosis, and thyroid follicular cell hyperplasia of the thyroid gland but not in their pathophysiology.</p><p>Both cellular and humoral factors may contribute to the thyroid injury and hypothyroidism in chronic autoimmune thyroiditis. Cytotoxic T cells may directly destroy thyroid cells. In addition, more than 90 percent of patients with chronic autoimmune thyroiditis have high serum concentrations of autoantibodies to thyroglobulin, thyroid peroxidase (thyroid microsomal antigen) [<a href="#rid2">2,3</a>], or the thyroid sodium-iodide transporter  (<a class="graphic graphic_table graphicRef76522" href="/z/d/graphic/76522.html" rel="external">table 2</a>) [<a href="#rid4">4</a>]. These antibodies have little, if any, functional activity. Many patients also have antibodies that block the action of TSH on the TSH receptor or that are cytotoxic to thyroid cells [<a href="#rid5">5,6</a>]. (See  <a class="medical medical_review" href="/z/d/html/7854.html" rel="external">"Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)"</a>.)</p><p>Serum antithyroid antibodies need <strong>not</strong> be measured routinely in patients with overt primary hypothyroidism, because almost all have chronic autoimmune thyroiditis. However, a test for antithyroid peroxidase antibodies may be useful to predict the likelihood of progression to permanent overt hypothyroidism in patients with subclinical hypothyroidism or those with painless (silent) thyroiditis or postpartum thyroiditis.</p><p class="headingAnchor" id="H4"><span class="h3">Prevalence</span><span class="headingEndMark"> — </span>In community surveys, high serum antithyroid peroxidase antibody concentrations are found in approximately 5 percent of adults and approximately 15 percent of older women  (<a class="graphic graphic_table graphicRef76522" href="/z/d/graphic/76522.html" rel="external">table 2</a>) [<a href="#rid7">7-9</a>]. The frequency of subclinical hypothyroidism is similar and that of overt hypothyroidism varies from 0.1 to 2 percent [<a href="#rid10">10</a>]. In one population-based study, the overall incidence of autoimmune thyroiditis was 46.4 per 1000 subjects during a 20-year period [<a href="#rid11">11</a>].</p><p>Hypothyroidism is much (five to eight times) more common in women than men. The majority of those who are hypothyroid have a goiter, but not all who have a goiter and circulating antithyroid antibodies have hypothyroidism.</p><p>In the United States National Health and Nutrition Examination Survey (NHANES III), 13,344 people without known thyroid disease had measurements of serum TSH, T4, thyroglobulin antibodies, and thyroid peroxidase antibodies with the following results [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypothyroidism was found in 4.6 percent (0.3 percent overt and 4.3 percent subclinical).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperthyroidism was found in 1.3 percent (0.5 percent overt and 0.7 percent subclinical).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum thyroglobulin antibody concentrations were high in 10 percent and serum thyroid peroxidase antibody concentrations were high in 11 percent. The latter were associated with hypo- or hyperthyroidism, while the former were not.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mean serum TSH concentrations were significantly lower in Black (1.7 percent) than in White or Mexican Americans.</p><p></p><p>Thus, a significant proportion of the United States population has laboratory evidence of thyroid disease, suggesting that routine screening would be useful.</p><p class="headingAnchor" id="H5"><span class="h3">Natural history</span><span class="headingEndMark"> — </span>The usual course of Hashimoto's thyroiditis is gradual loss of thyroid function. Among patients with this disorder who have mild (subclinical) hypothyroidism, exhibited as slight increases in TSH and the presence of thyroid antibodies, overt hypothyroidism occurs at a rate of approximately 5 percent per year [<a href="#rid8">8,13</a>]. Chronic autoimmune thyroiditis is usually, but not always, permanent. Repeat biopsies reveal little histologic change, nor do serum antithyroid antibody concentrations change in most patients [<a href="#rid14">14</a>]. However, a few patients have remissions and no longer need T4 therapy, indicating that the hypothyroidism is not always caused by destruction of the thyroid gland. One study, as an example, evaluated 15 Japanese patients with TSH-receptor blocking antibodies in whom the antibodies later disappeared; six remained euthyroid for several years after T4 therapy was discontinued [<a href="#rid5">5</a>]. Whether disappearance of antithyroid peroxidase antibodies can be used to predict remission of hypothyroidism is not known.</p><p class="headingAnchor" id="H6"><span class="h3">Susceptibility and risk factors</span><span class="headingEndMark"> — </span>Chronic autoimmune thyroiditis is more common in women, especially older women. Whether the increase in risk in the latter group is due to estrogen deficiency or age is not known. Chronic autoimmune thyroiditis is also the most common cause of hypothyroidism in children, being reported as early as one and two years of age [<a href="#rid15">15</a>].</p><p>Chronic autoimmune thyroiditis is associated with several polymorphisms in the genes for human leukocyte antigen (HLA), T-cell antigen receptors, and other immunomodulatory molecules, suggesting a role for genetic susceptibility [<a href="#rid16">16,17</a>]. However, the relative risk is approximately two for most of the associations, which also vary considerably among different racial and ethnic groups. Turner syndrome and Down syndrome are both associated with a higher than expected rate of autoimmune thyroiditis [<a href="#rid18">18,19</a>]. (See  <a class="medical medical_review" href="/z/d/html/169.html" rel="external">"Pathogenesis of autoimmune adrenal insufficiency"</a>.)</p><p>Whatever the factors mediating genetic susceptibility, patients with chronic autoimmune thyroiditis are more likely to have a personal or family history of other autoimmune diseases, such as adrenal insufficiency and insulin-dependent diabetes mellitus [<a href="#rid20">20</a>]. Chronic autoimmune thyroiditis is one of the components of polyglandular autoimmune syndrome 2. (See  <a class="medical medical_review" href="/z/d/html/166.html" rel="external">"Causes of primary adrenal insufficiency (Addison disease)", section on 'Type 2 (polygenic)'</a>.)</p><p>Other risk factors include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>High iodine intake has been associated with Hashimoto's thyroiditis. Serum antithyroid antibody concentrations increase after dietary iodine intake is increased in endemic goiter regions [<a href="#rid21">21</a>]. Pharmacologic amounts of iodine are known to cause hypothyroidism in patients with chronic autoimmune thyroiditis. (See <a class="local">'Iodine'</a> below and  <a class="medical medical_review" href="/z/d/html/7844.html" rel="external">"Iodine-induced thyroid dysfunction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Relative <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">selenium</a> deficiency has been associated with Hashimoto's thyroiditis and hypothyroidism [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Childhood weight gain and being overweight or obese at age 14 years have been associated with thyroid autoimmunity and hypothyroidism [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cigarette smoking increased the risk of hypothyroidism in patients <strong>with</strong> autoimmune thyroid disease [<a href="#rid24">24</a>]. However, in a population-based study, smoking was associated with a lower prevalence of hypothyroidism and a higher prevalence of hyperthyroidism [<a href="#rid25">25</a>].</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Iatrogenic disease</span><span class="headingEndMark"> — </span>Thyroidectomy, radioiodine treatment, and external radiation therapy are well-known causes of hypothyroidism.</p><p class="headingAnchor" id="H9"><span class="h3">Thyroidectomy</span><span class="headingEndMark"> — </span>Because T4 has a half-life of seven days, hypothyroidism occurs within two to four weeks after total thyroidectomy. The time course after subtotal thyroidectomy in patients with Graves' hyperthyroidism is more variable. It occurs within the first year after surgery in the majority of patients; among those who are euthyroid at one year, approximately 0.5 to 1 percent become hypothyroid each year thereafter [<a href="#rid26">26,27</a>]. The late onset is presumably due to superimposed chronic autoimmune thyroiditis [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/7880.html" rel="external">"Surgical management of hyperthyroidism"</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Radioiodine therapy</span><span class="headingEndMark"> — </span>Radioiodine (I-131) therapy for Graves' hyperthyroidism can cause hypothyroidism weeks, months, or years later. The high-dose regimens preferred in most centers (to reduce the need for retreatment) result in hypothyroidism in the majority of patients within the first two to six months after therapy; the remainder become hypothyroid at a rate of 0.5 to 2 percent per year [<a href="#rid26">26,27,29</a>]. A significant minority of patients with toxic or nontoxic multinodular goiter or autonomously functioning thyroid adenomas also become hypothyroid after radioiodine therapy. (See  <a class="medical medical_review" href="/z/d/html/7879.html" rel="external">"Radioiodine in the treatment of hyperthyroidism"</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">External neck irradiation</span><span class="headingEndMark"> — </span>External irradiation of the neck (in doses of 25 Gy [2500 rads] or more) also causes hypothyroidism. The effect is dose dependent, the onset is gradual, and many patients have subclinical hypothyroidism for several years before developing overt disease. (See  <a class="medical medical_review" href="/z/d/html/93313.html" rel="external">"Endocrinopathies in cancer survivors and others exposed to cytotoxic therapies during childhood", section on 'Primary hypothyroidism'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Hodgkin lymphoma – One study evaluated 1677 patients with Hodgkin lymphoma who were treated with neck radiation and were followed for up to 20 years; the cumulative incidence of hypothyroidism was 30 percent [<a href="#rid30">30</a>] and, in one study, was more common in patients who had lymphangiography [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperfractionated radiation therapy – Data from children suggest that hyperfractionated radiation may cause fewer cases of hypothyroidism than conventional therapy [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Head and neck cancer – A thyroid-destructive effect is also seen with total body irradiation [<a href="#rid33">33</a>] and external radiation therapy in patients with head and neck cancer. In one study, 53 percent of irradiated patients with head and neck carcinoma developed hypothyroidism [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/3365.html" rel="external">"Management of late complications of head and neck cancer and its treatment", section on 'Thyroid disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Breast cancer – External radiation for breast cancer may also lead to hypothyroidism, depending on the area irradiated and whether the thyroid is shielded. In a small study (n = 40), 15 percent of irradiated patients and 5 percent of controls developed hypothyroidism [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nuclear accident – Thyroid irradiation also may promote the formation of antithyroid antibodies. Studies in children and adolescents from Belarus who were exposed to radioactive fallout after the nuclear accident at Chernobyl have noted an increased prevalence of antithyroglobulin or antithyroid peroxidase antibodies at six to eight years (19.5 versus 3.8 percent in unexposed children) [<a href="#rid36">36</a>]. Thyroid function was normal in these children; their future risk of hypothyroidism is not known. (See  <a class="medical medical_review" href="/z/d/html/7854.html" rel="external">"Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)", section on 'Radiation exposure'</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Iodine</span><span class="headingEndMark"> — </span>Both iodine deficiency and excess can cause hypothyroidism. Iodine deficiency is the most common cause of hypothyroidism (and goiter) worldwide [<a href="#rid37">37</a>]. When defined as an iodine intake less than 100 mcg/day, it affects approximately two billion people, many of whom live in mountainous areas. Iodine deficiency is rare in North America because iodized salt is ubiquitous and there are many other sources of iodine in the diet; it persists in parts of Europe because iodized salt is less frequently consumed in some countries. In certain regions (Africa, South America), the effect of iodine deficiency is magnified by consumption of foodstuffs such as cassava roots that contain cyanoglucosides; these substances are metabolized to thiocyanate, which has antithyroid properties and magnifies the effects of iodine deficiency [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/7828.html" rel="external">"Iodine deficiency disorders"</a>.)</p><p>Iodine excess also can cause hypothyroidism by inhibiting iodide organification and T4 and T3 synthesis (the Wolff-Chaikoff effect). Normal subjects quickly "escape" from this effect of iodine. However, patients with abnormal thyroid glands do not, and they can become hypothyroid if given iodine for more than a few days. Patients at risk for iodine-induced hypothyroidism include those with chronic autoimmune thyroiditis and those who have had a partial thyroidectomy or a history of radioiodine therapy, painless, postpartum, or subacute granulomatous thyroiditis. The excess iodine can be derived from health tonics, cough medicines, kelp tablets and other dietary supplements, iodine-containing substances (eg, Betadine) applied to the skin or vagina, drugs such as <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, and radiographic contrast agents  (<a class="graphic graphic_table graphicRef60901" href="/z/d/graphic/60901.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/7844.html" rel="external">"Iodine-induced thyroid dysfunction"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Drugs</span><span class="headingEndMark"> — </span>The drugs given intentionally to decrease thyroid secretion (<a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> and <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">propylthiouracil</a> [and perchlorate]) can cause hypothyroidism. None have other uses and, therefore, should not be the cause of hypothyroidism in patients who do not have a history of hyperthyroidism. <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">Ethionamide</a>, an antimycobacterial drug used as a second-line agent for the treatment of multidrug-resistant tuberculosis, is structurally similar to methimazole and is a rare cause of hypothyroidism [<a href="#rid39">39</a>].</p><p>Drugs used to treat nonthyroid conditions that can cause hypothyroidism include <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> carbonate, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> (an iodine-containing drug), interferon alfa, interleukin-2, tyrosine kinase inhibitors, and checkpoint inhibitor immunotherapy (eg, <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>, <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, and <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>)  (<a class="graphic graphic_table graphicRef50439" href="/z/d/graphic/50439.html" rel="external">table 4</a>). Serum TSH should be measured when patients develop possible hypothyroid symptoms and, at minimum, every 6 to 12 months in patients taking these drugs. (See  <a class="medical medical_review" href="/z/d/html/7843.html" rel="external">"Lithium and the thyroid"</a> and  <a class="medical medical_review" href="/z/d/html/7834.html" rel="external">"Amiodarone and thyroid dysfunction"</a> and  <a class="medical medical_review" href="/z/d/html/7824.html" rel="external">"Overview of thyroiditis", section on 'Drug-induced thyroiditis'</a> and  <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Autoimmune thyroid disease'</a>.)</p><p>Oral tyrosine kinase inhibitors (eg, <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a>, motesanib) used for the treatment of gastrointestinal stromal tumors (GISTs), renal cell carcinoma, hepatocellular cancer, chronic myeloid leukemia, and in other cancers can cause hypothyroidism [<a href="#rid40">40</a>]. Of the kinase inhibitors, sunitinib appears to cause thyroid dysfunction most frequently, occurring in 15 of 42 patients (36 percent) in one report [<a href="#rid41">41</a>] and 21 of 40 patients in another report [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/z/d/html/7845.html" rel="external">"Drug interactions with thyroid hormones", section on 'Tyrosine kinase inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Thyroid dysfunction'</a>.)</p><p>The RET inhibitor, <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">selpercatinib</a>, inhibits T4 to T3 conversion and can cause hypothyroidism, predominately in levothyroxine-treated patients [<a href="#rid43">43</a>].</p><p>In addition, patients with hypothyroidism who are taking T4 may become hypothyroid again, if given drugs that decrease T4 absorption (such as <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a> and iron salts), increase its clearance (such as <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> and <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>), or decrease T4-to-T3 conversion (<a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>). Thus, if the offending drug cannot be stopped, the T4 dose may need to be increased. (See  <a class="medical medical_review" href="/z/d/html/7845.html" rel="external">"Drug interactions with thyroid hormones"</a>.)</p><p class="headingAnchor" id="H84729431"><span class="h2">Environmental exposures</span><span class="headingEndMark"> — </span>Epidemiologic studies have reported an increased risk of hypothyroidism after exposure to some environmental toxins and contaminants [<a href="#rid44">44</a>]. As an example, polybrominated diphenyl ethers (PBDEs [flame retardants]) exposure has been associated with hypothyroidism (prevalence ratio 1.7, 95% CI 1-3) [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/z/d/html/113968.html" rel="external">"Endocrine-disrupting chemicals", section on 'Thyroid disease'</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Infiltrative disease</span><span class="headingEndMark"> — </span>Infiltrative diseases, such as fibrous thyroiditis (Reidel's thyroiditis), hemochromatosis, scleroderma, leukemia, and cystinosis, are rare causes of hypothyroidism [<a href="#rid46">46</a>]. Amyloid goiter is likewise uncommon, although, when present, it often results in hypothyroidism. In one series, as an example, 5 of 19 patients (26 percent) with amyloid goiter were hypothyroid [<a href="#rid47">47</a>]. Infections of the thyroid, as with <em>Mycobacterium tuberculosis</em> and <em>Pneumocystis carinii</em>, occasionally damage the thyroid enough to cause hypothyroidism. (See  <a class="medical medical_review" href="/z/d/html/7861.html" rel="external">"Infiltrative thyroid disease"</a>.)</p><p>Sarcoid infiltration can cause goiter. However, patients with sarcoidosis have a higher than expected prevalence of thyroid antibodies; thus, hypothyroidism in these patients also may have an autoimmune etiology [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Hypothyroidism in infants and children</span><span class="headingEndMark"> — </span>The most common causes of congenital hypothyroidism are agenesis and dysgenesis of the thyroid, but a few have inherited defects in thyroid hormone biosynthesis or are delivered by mothers who were receiving an antithyroid drug for hyperthyroidism [<a href="#rid49">49</a>]. Among children who become hypothyroid later, the most common cause is chronic autoimmune thyroiditis. (See  <a class="medical medical_review" href="/z/d/html/5836.html" rel="external">"Clinical features and detection of congenital hypothyroidism"</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Transient hypothyroidism</span><span class="headingEndMark"> — </span>Hypothyroidism occurs transiently during the course of several types of thyroiditis. (See  <a class="medical medical_review" href="/z/d/html/7824.html" rel="external">"Overview of thyroiditis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with silent (or postpartum) thyroiditis and subacute (or granulomatous) thyroiditis have inflammation of thyroid tissue with transient hyperthyroidism, frequently followed by transient hypothyroidism, then recovery of thyroid function. The hypothyroidism is usually more severe in patients with subacute thyroiditis, while occasional patients with painless thyroiditis will present during the hypothyroid phase of the illness.</p><p></p><p class="bulletIndent1">Transient hypothyroidism can last from a few weeks to as long as six months in these disorders. Patients with minimal symptoms may not require therapy. Those with symptomatic hypothyroidism should be treated with T4, which can be given for several months, then discontinued. A normal serum TSH value six weeks later will confirm the recovery of thyroid function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among women with postpartum thyroiditis, approximately 20 to 30 percent have hyperthyroidism followed by transient hypothyroidism and 40 to 50 percent have only transient hypothyroidism. In either instance, the hypothyroidism lasts several weeks to a few months. These figures are based on serial biochemical testing; the proportion of women with symptoms is smaller, and fewer need replacement therapy. (See  <a class="medical medical_review" href="/z/d/html/7831.html" rel="external">"Postpartum thyroiditis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients who undergo subtotal thyroidectomy become hypothyroid after four to eight weeks but recover several weeks or months later. The probable explanation is that they have enough remaining thyroid tissue to maintain normal thyroid secretion once its growth has been stimulated by TSH.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Many patients with Graves' hyperthyroidism whose glands were not completely ablated by radioiodine and who have some remaining thyroid tissue may have transient hypothyroidism after radioactive iodine therapy because TSH secretion, previously low, does not increase appropriately in response to low serum T4 concentrations for several weeks or months.</p><p></p><p>Withdrawal of exogenous thyroid therapy in patients who do not have hypothyroidism and in whom the therapy suppressed endogenous pituitary-thyroid function is sometimes followed by transient hypothyroidism until TSH secretion and then thyroid secretion resumes [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H18"><span class="h1">SECONDARY AND TERTIARY (CENTRAL) HYPOTHYROIDISM</span><span class="headingEndMark"> — </span>Secondary hypothyroidism is that caused by TSH deficiency, and tertiary hypothyroidism is caused by thyrotropin-releasing hormone (TRH) deficiency. Less than 1 percent of patients with hypothyroidism have one of these forms of central hypothyroidism. (See  <a class="medical medical_review" href="/z/d/html/7849.html" rel="external">"Central hypothyroidism"</a>.)</p><p>Most patients with central hypothyroidism have low or normal serum TSH concentrations (but inappropriately low in the presence of low serum T4 and T3 concentrations). However, a few patients with TSH deficiency have slightly high serum TSH values because they secrete TSH that is less glycosylated and therefore has less biological activity than normal TSH (but is normally immunoreactive).</p><p>Secondary hypothyroidism can be caused by any of the causes of hypopituitarism, most often a pituitary tumor [<a href="#rid51">51</a>] (see  <a class="medical medical_review" href="/z/d/html/6636.html" rel="external">"Causes of hypopituitarism"</a>). Most patients with pituitary microadenomas are euthyroid, whereas 10 to 25 of those with macroadenomas are hypothyroid, either initially or after surgical or radiation therapy. (A few patients who are initially hypothyroid become euthyroid after resection of a pituitary macroadenoma.)</p><p>Other causes of secondary hypothyroidism include postpartum pituitary necrosis (Sheehan syndrome), trauma, hypophysitis, nonpituitary tumors such as craniopharyngiomas, infiltrative diseases, and inactivating mutations in the gene for either TSH or the TSH receptor [<a href="#rid52">52-56</a>] (see  <a class="medical medical_review" href="/z/d/html/5845.html" rel="external">"Resistance to thyrotropin and thyrotropin-releasing hormone"</a>). TSH deficiency may be isolated, but more often, it occurs in association with other pituitary hormone deficiencies. (See  <a class="medical medical_review" href="/z/d/html/6636.html" rel="external">"Causes of hypopituitarism"</a> and  <a class="medical medical_review" href="/z/d/html/6637.html" rel="external">"Clinical manifestations of hypopituitarism"</a>.)</p><p>Tertiary hypothyroidism can be caused by any disorder that damages the hypothalamus or interferes with hypothalamic-pituitary portal blood flow, thereby preventing delivery of TRH to the pituitary [<a href="#rid51">51</a>]. It can also be caused by mutations in the gene for the TRH receptor [<a href="#rid57">57,58</a>]. Like TSH deficiency, TRH deficiency can be isolated or occur in combination with other hormonal deficiencies. Hypothalamic damage results from tumors, trauma, radiation therapy, or infiltrative diseases.</p><p>TSH deficiency and TRH deficiency cannot be distinguished by biochemical tests. Any patient with findings suggestive of central hypothyroidism should undergo magnetic resonance imaging (MRI) of the hypothalamus and pituitary. The results allow inferences to be made as to which hormone is deficient, but the distinction is of no practical importance with respect to the patient's hypothyroidism.</p><p class="headingAnchor" id="H19"><span class="h1">RESISTANCE TO THYROID HORMONE</span><span class="headingEndMark"> — </span>Resistance to thyroid hormone (RTH) is a rare disorder, usually inherited as an autosomal dominant trait. It is caused by mutations in the gene for the beta form of the T3 nuclear receptor. The abnormal receptors have a decreased affinity for T3, the physiologically active hormone within cells; they can also inhibit the action of the normal receptors [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/z/d/html/5827.html" rel="external">"Resistance to thyroid hormone and other defects in thyroid hormone action"</a>.)</p><p>This disorder is included here because a few patients with the syndrome have had findings indicating the presence of hypothyroidism in infancy, such as short stature, deafness, and intellectual disability. However, most patients with this disorder are euthyroid (some have a suggestion of hyperthyroidism, such as tachycardia). There may be an association between this disorder and attention deficit hyperactivity disorder (ADHD), and learning disabilities and hearing loss are significant problems [<a href="#rid59">59,60</a>].</p><p>These patients are often discovered by accident as a result of a thyroid test; the characteristic findings are high serum T4 and T3 concentrations, with a normal or high serum TSH concentration. These biochemical findings indicate that the pituitary thyrotroph cells are relatively resistant to T4 and T3 (as are other tissues) and also that high serum T4 and T3 concentrations can overcome the resistance.</p><p>Treatment is usually unnecessary, but T4 or T3 may be given if symptoms of hypothyroidism occur.</p><p class="headingAnchor" id="H373560900"><span class="h1">RESISTANCE TO THYROTROPIN AND THYROTROPIN-RELEASING HORMONE</span><span class="headingEndMark"> — </span>These rare disorders are due to inactivating mutations in the TSH or thyrotropin-releasing hormone (TRH) receptor genes, <em>PAX8</em> gene mutations, and mutations in the long arm or chromosome 15. Some of these patients are euthyroid due to compensation from high serum levels of TSH, while others are hypothyroid and benefit from treatment with <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a>. (See  <a class="medical medical_review" href="/z/d/html/5845.html" rel="external">"Resistance to thyrotropin and thyrotropin-releasing hormone"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">CONSUMPTIVE HYPOTHYROIDISM</span><span class="headingEndMark"> — </span>Consumptive hypothyroidism is a very rare form of hypothyroidism characterized by excessive degradation of thyroid hormone due to the ectopic production of the type 3 deiodinase, which metabolizes T4 to reverse T3 and T3 to T2. This has been described in vascular and fibrotic tumors and in patients with gastrointestinal stromal tumors (GISTs) [<a href="#rid61">61,62</a>].</p><p class="headingAnchor" id="H1714683086"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109155.html" rel="external">"Society guideline links: Hypothyroidism"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15438.html" rel="external">"Patient education: Hypothyroidism (underactive thyroid) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2179.html" rel="external">"Patient education: Hypothyroidism (underactive thyroid) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The cause of primary hypothyroidism in most patients is Hashimoto's thyroiditis. Other common causes should be evident because of a history of surgery, radioiodine, or external radiation to the neck, or the use of drugs associated with hypothyroidism  (<a class="graphic graphic_table graphicRef67769" href="/z/d/graphic/67769.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef50439" href="/z/d/graphic/50439.html" rel="external">table 4</a>). (See <a class="local">'Primary hypothyroidism'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infiltrative disorders, inherited defects in biosynthesis of thyroid hormone, and generalized resistance to thyroid hormone (RTH) are rare causes of hypothyroidism. (See <a class="local">'Infiltrative disease'</a> above and <a class="local">'Hypothyroidism in infants and children'</a> above and <a class="local">'Resistance to thyroid hormone'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Causes of transient hypothyroidism, such as painless or postpartum thyroiditis, should also always be considered to avoid unnecessary lifelong treatment with thyroxine (T4). (See <a class="local">'Transient hypothyroidism'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is critical that secondary or central hypothyroidism is not missed; measurement of both thyroid-stimulating hormone (TSH) and free T4 should avoid misdiagnosis. (See <a class="local">'Secondary and tertiary (central) hypothyroidism'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev 1994; 15:788.</a></li><li><a class="nounderline abstract_t">Mariotti S, Caturegli P, Piccolo P, et al. Antithyroid peroxidase autoantibodies in thyroid diseases. J Clin Endocrinol Metab 1990; 71:661.</a></li><li><a class="nounderline abstract_t">Nordyke RA, Gilbert FI Jr, Miyamoto LA, Fleury KA. The superiority of antimicrosomal over antithyroglobulin antibodies for detecting Hashimoto's thyroiditis. Arch Intern Med 1993; 153:862.</a></li><li><a class="nounderline abstract_t">Endo T, Kaneshige M, Nakazato M, et al. Autoantibody against thyroid iodide transporter in the sera from patients with Hashimoto's thyroiditis possesses iodide transport inhibitory activity. Biochem Biophys Res Commun 1996; 228:199.</a></li><li><a class="nounderline abstract_t">Takasu N, Yamada T, Takasu M, et al. Disappearance of thyrotropin-blocking antibodies and spontaneous recovery from hypothyroidism in autoimmune thyroiditis. N Engl J Med 1992; 326:513.</a></li><li><a class="nounderline abstract_t">Bogner U, Hegedüs L, Hansen JM, et al. Thyroid cytotoxic antibodies in atrophic and goitrous autoimmune thyroiditis. Eur J Endocrinol 1995; 132:69.</a></li><li><a class="nounderline abstract_t">Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977; 7:481.</a></li><li><a class="nounderline abstract_t">Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995; 43:55.</a></li><li><a class="nounderline abstract_t">Sawin CT, Castelli WP, Hershman JM, et al. The aging thyroid. Thyroid deficiency in the Framingham Study. Arch Intern Med 1985; 145:1386.</a></li><li class="breakAll">Vanderpump MP, Tunbridge WM. The epidemiology of thyroid diseases. In: The thyroid: A fundamental and clinical text, 8th, Braverman LE, Utiger RD (Eds), Lippincott Williams and Wilkins, Philadelphia 2000. p.467.</li><li><a class="nounderline abstract_t">Rallison ML, Dobyns BM, Meikle AW, et al. Natural history of thyroid abnormalities: prevalence, incidence, and regression of thyroid diseases in adolescents and young adults. Am J Med 1991; 91:363.</a></li><li><a class="nounderline abstract_t">Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87:489.</a></li><li><a class="nounderline abstract_t">Huber G, Staub JJ, Meier C, et al. Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab 2002; 87:3221.</a></li><li><a class="nounderline abstract_t">Hayashi Y, Tamai H, Fukata S, et al. A long term clinical, immunological, and histological follow-up study of patients with goitrous chronic lymphocytic thyroiditis. J Clin Endocrinol Metab 1985; 61:1172.</a></li><li><a class="nounderline abstract_t">Foley TP Jr, Abbassi V, Copeland KC, Draznin MB. Brief report: hypothyroidism caused by chronic autoimmune thyroiditis in very young infants. N Engl J Med 1994; 330:466.</a></li><li><a class="nounderline abstract_t">Dayan CM, Daniels GH. Chronic autoimmune thyroiditis. N Engl J Med 1996; 335:99.</a></li><li><a class="nounderline abstract_t">Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocr Rev 2003; 24:694.</a></li><li><a class="nounderline abstract_t">Chiovato L, Larizza D, Bendinelli G, et al. Autoimmune hypothyroidism and hyperthyroidism in patients with Turner's syndrome. Eur J Endocrinol 1996; 134:568.</a></li><li><a class="nounderline abstract_t">Karlsson B, Gustafsson J, Hedov G, et al. Thyroid dysfunction in Down's syndrome: relation to age and thyroid autoimmunity. Arch Dis Child 1998; 79:242.</a></li><li><a class="nounderline abstract_t">Fallahi P, Ferrari SM, Ruffilli I, et al. The association of other autoimmune diseases in patients with autoimmune thyroiditis: Review of the literature and report of a large series of patients. Autoimmun Rev 2016; 15:1125.</a></li><li><a class="nounderline abstract_t">Boukis MA, Koutras DA, Souvatzoglou A, et al. Thyroid hormone and immunological studies in endemic goiter. J Clin Endocrinol Metab 1983; 57:859.</a></li><li><a class="nounderline abstract_t">Wu Q, Rayman MP, Lv H, et al. Low Population Selenium Status Is Associated With Increased Prevalence of Thyroid Disease. J Clin Endocrinol Metab 2015; 100:4037.</a></li><li><a class="nounderline abstract_t">Ong KK, Kuh D, Pierce M, et al. Childhood weight gain and thyroid autoimmunity at age 60-64 years: the 1946 British birth cohort study. J Clin Endocrinol Metab 2013; 98:1435.</a></li><li><a class="nounderline abstract_t">Fukata S, Kuma K, Sugawara M. Relationship between cigarette smoking and hypothyroidism in patients with Hashimoto's thyroiditis. J Endocrinol Invest 1996; 19:607.</a></li><li><a class="nounderline abstract_t">Asvold BO, Bjøro T, Nilsen TI, Vatten LJ. Tobacco smoking and thyroid function: a population-based study. Arch Intern Med 2007; 167:1428.</a></li><li><a class="nounderline abstract_t">Sridama V, McCormick M, Kaplan EL, et al. Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease. N Engl J Med 1984; 311:426.</a></li><li><a class="nounderline abstract_t">Franklyn JA, Daykin J, Drolc Z, et al. Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin Endocrinol (Oxf) 1991; 34:71.</a></li><li><a class="nounderline abstract_t">McHenry CR, Slusarczyk SJ. Hypothyroidisim following hemithyroidectomy: incidence, risk factors, and management. Surgery 2000; 128:994.</a></li><li><a class="nounderline abstract_t">Cunnien AJ, Hay ID, Gorman CA, et al. Radioiodine-induced hypothyroidism in Graves' disease: factors associated. J Nucl Med 1982; 23:978.</a></li><li><a class="nounderline abstract_t">Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med 1991; 325:599.</a></li><li><a class="nounderline abstract_t">Fein DA, Hanlon AL, Corn BW, et al. The influence of lymphangiography on the development of hypothyroidism in patients irradiated for Hodgkin's disease. Int J Radiat Oncol Biol Phys 1996; 36:13.</a></li><li><a class="nounderline abstract_t">Chin D, Sklar C, Donahue B, et al. Thyroid dysfunction as a late effect in survivors of pediatric medulloblastoma/primitive neuroectodermal tumors: a comparison of hyperfractionated versus conventional radiotherapy. Cancer 1997; 80:798.</a></li><li><a class="nounderline abstract_t">Littley MD, Shalet SM, Morgenstern GR, Deakin DP. Endocrine and reproductive dysfunction following fractionated total body irradiation in adults. Q J Med 1991; 78:265.</a></li><li><a class="nounderline abstract_t">Alba JR, Basterra J, Ferrer JC, et al. Hypothyroidism in patients treated with radiotherapy for head and neck carcinoma: standardised long-term follow-up study. J Laryngol Otol 2016; 130:478.</a></li><li><a class="nounderline abstract_t">Tunio MA, Al Asiri M, Bayoumi Y, et al. Is thyroid gland an organ at risk in breast cancer patients treated with locoregional radiotherapy? Results of a pilot study. J Cancer Res Ther 2015; 11:684.</a></li><li><a class="nounderline abstract_t">Pacini F, Vorontsova T, Molinaro E, et al. Prevalence of thyroid autoantibodies in children and adolescents from Belarus exposed to the Chernobyl radioactive fallout. Lancet 1998; 352:763.</a></li><li><a class="nounderline abstract_t">Andersson M, Takkouche B, Egli I, et al. Current global iodine status and progress over the last decade towards the elimination of iodine deficiency. Bull World Health Organ 2005; 83:518.</a></li><li><a class="nounderline abstract_t">Bourdoux P, Delange F, Gerard M, et al. Evidence that cassava ingestion increases thiocyanate formation: a possible etiologic factor in endemic goiter. J Clin Endocrinol Metab 1978; 46:613.</a></li><li><a class="nounderline abstract_t">McDonnell ME, Braverman LE, Bernardo J. Hypothyroidism due to ethionamide. N Engl J Med 2005; 352:2757.</a></li><li><a class="nounderline abstract_t">Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst 2011; 103:1572.</a></li><li><a class="nounderline abstract_t">Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006; 145:660.</a></li><li><a class="nounderline abstract_t">Wong E, Rosen LS, Mulay M, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007; 17:351.</a></li><li><a class="nounderline abstract_t">Boucai L, Salas-Lucia F, Krishnamoorthy GP, et al. Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase. JCO Precis Oncol 2022; 6:e2100496.</a></li><li><a class="nounderline abstract_t">Pearce EN, Braverman LE. Environmental pollutants and the thyroid. Best Pract Res Clin Endocrinol Metab 2009; 23:801.</a></li><li><a class="nounderline abstract_t">Oulhote Y, Chevrier J, Bouchard MF. Exposure to Polybrominated Diphenyl Ethers (PBDEs) and Hypothyroidism in Canadian Women. J Clin Endocrinol Metab 2016; 101:590.</a></li><li class="breakAll">Barsano CP. Other forms of primary hypothyroidism. In: The thyroid: A fundamental and clinical text, 7th, Braverman LE, Utiger RD (Eds), Lippincott-Raven, Philadelphia 1996. p.768.</li><li><a class="nounderline abstract_t">Kimura H, Yamashita S, Ashizawa K, et al. Thyroid dysfunction in patients with amyloid goitre. Clin Endocrinol (Oxf) 1997; 46:769.</a></li><li><a class="nounderline abstract_t">Nakamura H, Genma R, Mikami T, et al. High incidence of positive autoantibodies against thyroid peroxidase and thyroglobulin in patients with sarcoidosis. Clin Endocrinol (Oxf) 1997; 46:467.</a></li><li><a class="nounderline abstract_t">Fisher DA, Klein AH. Thyroid development and disorders of thyroid function in the newborn. N Engl J Med 1981; 304:702.</a></li><li><a class="nounderline abstract_t">Vagenakis AG, Braverman LE, Azizi F, et al. Recovery of pituitary thyrotropic function after withdrawal of prolonged thyroid-suppression therapy. N Engl J Med 1975; 293:681.</a></li><li><a class="nounderline abstract_t">Samuels MH, Ridgway EC. Central hypothyroidism. Endocrinol Metab Clin North Am 1992; 21:903.</a></li><li><a class="nounderline abstract_t">Doeker BM, Pfäffle RW, Pohlenz J, Andler W. Congenital central hypothyroidism due to a homozygous mutation in the thyrotropin beta-subunit gene follows an autosomal recessive inheritance. J Clin Endocrinol Metab 1998; 83:1762.</a></li><li><a class="nounderline abstract_t">Medeiros-Neto G, Herodotou DT, Rajan S, et al. A circulating, biologically inactive thyrotropin caused by a mutation in the beta subunit gene. J Clin Invest 1996; 97:1250.</a></li><li><a class="nounderline abstract_t">Sunthornthepvarakui T, Gottschalk ME, Hayashi Y, Refetoff S. Brief report: resistance to thyrotropin caused by mutations in the thyrotropin-receptor gene. N Engl J Med 1995; 332:155.</a></li><li><a class="nounderline abstract_t">Abramowicz MJ, Duprez L, Parma J, et al. Familial congenital hypothyroidism due to inactivating mutation of the thyrotropin receptor causing profound hypoplasia of the thyroid gland. J Clin Invest 1997; 99:3018.</a></li><li><a class="nounderline abstract_t">Gagné N, Parma J, Deal C, et al. Apparent congenital athyreosis contrasting with normal plasma thyroglobulin levels and associated with inactivating mutations in the thyrotropin receptor gene: are athyreosis and ectopic thyroid distinct entities? J Clin Endocrinol Metab 1998; 83:1771.</a></li><li><a class="nounderline abstract_t">Collu R, Tang J, Castagné J, et al. A novel mechanism for isolated central hypothyroidism: inactivating mutations in the thyrotropin-releasing hormone receptor gene. J Clin Endocrinol Metab 1997; 82:1561.</a></li><li><a class="nounderline abstract_t">Koulouri O, Nicholas AK, Schoenmakers E, et al. A Novel Thyrotropin-Releasing Hormone Receptor Missense Mutation (P81R) in Central Congenital Hypothyroidism. J Clin Endocrinol Metab 2016; 101:847.</a></li><li><a class="nounderline abstract_t">Brucker-Davis F, Skarulis MC, Grace MB, et al. Genetic and clinical features of 42 kindreds with resistance to thyroid hormone. The National Institutes of Health Prospective Study. Ann Intern Med 1995; 123:572.</a></li><li><a class="nounderline abstract_t">Hauser P, Zametkin AJ, Martinez P, et al. Attention deficit-hyperactivity disorder in people with generalized resistance to thyroid hormone. N Engl J Med 1993; 328:997.</a></li><li><a class="nounderline abstract_t">Ruppe MD, Huang SA, Jan de Beur SM. Consumptive hypothyroidism caused by paraneoplastic production of type 3 iodothyronine deiodinase. Thyroid 2005; 15:1369.</a></li><li><a class="nounderline abstract_t">Maynard MA, Marino-Enriquez A, Fletcher JA, et al. Thyroid hormone inactivation in gastrointestinal stromal tumors. N Engl J Med 2014; 370:1327.</a></li></ol></div><div id="topicVersionRevision">Topic 7886 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7705281" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Autoimmune thyroid disease: further developments in our understanding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2168432" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Antithyroid peroxidase autoantibodies in thyroid diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8466378" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The superiority of antimicrosomal over antithyroglobulin antibodies for detecting Hashimoto's thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8912659" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Autoantibody against thyroid iodide transporter in the sera from patients with Hashimoto's thyroiditis possesses iodide transport inhibitory activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1732791" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Disappearance of thyrotropin-blocking antibodies and spontaneous recovery from hypothyroidism in autoimmune thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7850011" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Thyroid cytotoxic antibodies in atrophic and goitrous autoimmune thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/598014" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The spectrum of thyroid disease in a community: the Whickham survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7641412" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4026469" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The aging thyroid. Thyroid deficiency in the Framingham Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4026469" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The aging thyroid. Thyroid deficiency in the Framingham Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1951380" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Natural history of thyroid abnormalities: prevalence, incidence, and regression of thyroid diseases in adolescents and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11836274" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12107228" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3840493" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A long term clinical, immunological, and histological follow-up study of patients with goitrous chronic lymphocytic thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8289852" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Brief report: hypothyroidism caused by chronic autoimmune thyroiditis in very young infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8649497" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Chronic autoimmune thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14570752" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8664977" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Autoimmune hypothyroidism and hyperthyroidism in patients with Turner's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9875020" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Thyroid dysfunction in Down's syndrome: relation to age and thyroid autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27639841" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The association of other autoimmune diseases in patients with autoimmune thyroiditis: Review of the literature and report of a large series of patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6309889" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Thyroid hormone and immunological studies in endemic goiter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26305620" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Low Population Selenium Status Is Associated With Increased Prevalence of Thyroid Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23436917" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Childhood weight gain and thyroid autoimmunity at age 60-64 years: the 1946 British birth cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8957745" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Relationship between cigarette smoking and hypothyroidism in patients with Hashimoto's thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17620538" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Tobacco smoking and thyroid function: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6205272" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2004475" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Long-term follow-up of treatment of thyrotoxicosis by three different methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11114634" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hypothyroidisim following hemithyroidectomy: incidence, risk factors, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6897075" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Radioiodine-induced hypothyroidism in Graves' disease: factors associated.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1861693" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Thyroid diseases after treatment of Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8823254" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The influence of lymphangiography on the development of hypothyroidism in patients irradiated for Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9264364" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Thyroid dysfunction as a late effect in survivors of pediatric medulloblastoma/primitive neuroectodermal tumors: a comparison of hyperfractionated versus conventional radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2047520" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Endocrine and reproductive dysfunction following fractionated total body irradiation in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26975210" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hypothyroidism in patients treated with radiotherapy for head and neck carcinoma: standardised long-term follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26881502" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Is thyroid gland an organ at risk in breast cancer patients treated with locoregional radiotherapy? Results of a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9737280" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Prevalence of thyroid autoantibodies in children and adolescents from Belarus exposed to the Chernobyl radioactive fallout.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16175826" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Current global iodine status and progress over the last decade towards the elimination of iodine deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/755045" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Evidence that cassava ingestion increases thiocyanate formation: a possible etiologic factor in endemic goiter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15987931" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Hypothyroidism due to ethionamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22010182" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Thyroid dysfunction from antineoplastic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17088579" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17465866" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35704797" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19942155" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Environmental pollutants and the thyroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26606679" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Exposure to Polybrominated Diphenyl Ethers (PBDEs) and Hypothyroidism in Canadian Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26606679" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Exposure to Polybrominated Diphenyl Ethers (PBDEs) and Hypothyroidism in Canadian Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9274710" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Thyroid dysfunction in patients with amyloid goitre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9196610" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : High incidence of positive autoantibodies against thyroid peroxidase and thyroglobulin in patients with sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6258072" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Thyroid development and disorders of thyroid function in the newborn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/808728" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Recovery of pituitary thyrotropic function after withdrawal of prolonged thyroid-suppression therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1486881" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Central hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9589689" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Congenital central hypothyroidism due to a homozygous mutation in the thyrotropin beta-subunit gene follows an autosomal recessive inheritance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8636437" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A circulating, biologically inactive thyrotropin caused by a mutation in the beta subunit gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7528344" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Brief report: resistance to thyrotropin caused by mutations in the thyrotropin-receptor gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9185526" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Familial congenital hypothyroidism due to inactivating mutation of the thyrotropin receptor causing profound hypoplasia of the thyroid gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9589691" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Apparent congenital athyreosis contrasting with normal plasma thyroglobulin levels and associated with inactivating mutations in the thyrotropin receptor gene: are athyreosis and ectopic thyroid distinct entities?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9141550" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A novel mechanism for isolated central hypothyroidism: inactivating mutations in the thyrotropin-releasing hormone receptor gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26735259" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A Novel Thyrotropin-Releasing Hormone Receptor Missense Mutation (P81R) in Central Congenital Hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7677297" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Genetic and clinical features of 42 kindreds with resistance to thyroid hormone. The National Institutes of Health Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8450877" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Attention deficit-hyperactivity disorder in people with generalized resistance to thyroid hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16405410" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Consumptive hypothyroidism caused by paraneoplastic production of type 3 iodothyronine deiodinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24693892" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Thyroid hormone inactivation in gastrointestinal stromal tumors.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
